| abstract |
The present disclosure relates to methods of treating heart failure patients with reduced ejection fraction (HFrEF), with and without type 2 diabetes, with an SGLT2 inhibitor such as dapagliflozin. The methods disclosed herein reduce the risk of a combined outcome of a first episode of worsening heart failure (hospitalization for heart failure or an emergency visit for heart failure) or death from cardiovascular causes. Each of the three components of this combined result can also be reduced, as well as the total number of hospitalizations for heart failure and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life. |